UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 87

Sortiert nach

Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems

Nutrition, metabolism, and cardiovascular diseases, 2018-06, Vol.28 (6), p.533-542

2018

Volltextzugriff (PDF)

Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies

Cephalalgia, 2015-02, Vol.35 (2), p.118-131

2015

Volltextzugriff (PDF)

The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice

British journal of dermatology (1951), 2021-03, Vol.184 (3), p.581-583

2021

Volltextzugriff (PDF)

The Approaches to Assess Robustness of Disproportionality Findings in Pharmacovigilance. A Meta-Epidemiological Research

Drug safety, 2022-10, Vol.45 (10), p.1246-1247

2022

Volltextzugriff (PDF)

Medication use in Italian nursing homes: preliminary results from the national monitoring system

Frontiers in pharmacology, 2023-05, Vol.14, p.1128605-1128605

2023

Volltextzugriff (PDF)

Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K+ Channel Blockers

Journal of medicinal chemistry, 2002-08, Vol.45 (18), p.3844-3853

2002

Volltextzugriff (PDF)

Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems

Nutrition, metabolism, and cardiovascular diseases, 2017-12, Vol.27 (12), p.1098-1107

2017

Volltextzugriff (PDF)

Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction

Journal of the European Academy of Dermatology and Venereology, 2020-08, Vol.34 (8), p.e430-e431

2020

Volltextzugriff (PDF)

QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development

Medicinal research reviews, 2005-03, Vol.25 (2), p.133-166

2005

Volltextzugriff (PDF)

Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics

Alimentary pharmacology & therapeutics, 2004-02, Vol.19 (4), p.379-390

2004

Volltextzugriff (PDF)

Safety Profile of Sodium-Glucose Co-Transporter-2 Inhibitors: A Global Analysis of Pharmacovigilance Databases

Clinical therapeutics, 2017-08, Vol.39 (8), p.e38-e39

2017

Volltextzugriff (PDF)

Association between the use of proton pump inhibitors and cardiovascular events: A note of caution

Neurogastroenterology and motility, 2017-02, Vol.29 (2), p.n/a

2017

Volltextzugriff (PDF)

Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes an overview

Drug safety, 2002, Vol.25 (4), p.263-286

2002

Volltextzugriff (PDF)

Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit

Italian journal of pediatrics, 2017-04, Vol.43 (1), p.37-9, Article 37

2017

Volltextzugriff (PDF)

QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

European journal of clinical pharmacology, 2000-04, Vol.56 (1), p.1-18

2000

Volltextzugriff (PDF)

Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus

European journal of clinical pharmacology, 2001-06, Vol.57 (3), p.185-209

2001

Volltextzugriff (PDF)

Liver injury with dipeptidyl peptidase-4 (DPP-4) inhibitors (GLIPTINS): signals emerging from the us-fda adverse event reporting system

Clinical therapeutics, 2015-08, Vol.37 (8), p.e106-e106

2015

Volltextzugriff (PDF)

Hospitalisations by Drug interactions with nsaids in elderly poly-treated patients: outcome research on administrative databases

Clinical therapeutics, 2015-08, Vol.37 (8), p.e101-e102

2015

Volltextzugriff (PDF)

Oral Presentation: Investigating Hidden Networks in Spontaneous Reporting Systems

Drug safety, 2022-10, Vol.45 (10), p.1119-1120

2022

Volltextzugriff (PDF)

Oppenauer's oxidation by paraformaldehyde of piperonyl alcohol to heliotropine

Catalysis today, 2009-02, Vol.140 (1), p.112-116

2009

Volltextzugriff (PDF)

PP016—Exposure to antipsychotics with pro-arrhythmic risk: Combining adverse drug reactions with drug utilization data

Clinical therapeutics, 2013-08, Vol.35 (8), p.e22-e22

2013

Volltextzugriff (PDF)

Identifying Medications Underlying Communication Atypicalities: A Pharmacosurveillance Study Within the FDA Adverse Event Reporting System

Drug safety, 2022-10, Vol.45 (10), p.1134-1134

2022

Volltextzugriff (PDF)

What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System

Drug safety, 2022-10, Vol.45 (10), p.1242-1243

2022

Volltextzugriff (PDF)

Hyperacute Multisystem Toxicities with Immune Checkpoint Inhibitors in the FDA Adverse Event Reporting System: The Immune-Adversome

Drug safety, 2022-10, Vol.45 (10), p.1133-1133

2022

Volltextzugriff (PDF)

Previous psychiatric disorders and antipsychotic drugs in COVID-19 patients: early findings on possible worse outcome

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(84)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(43)
Life Sciences & Biomedicine
(35)
Humans
(29)
Pharmacology & Pharmacy
(15)
Pharmacovigilance
(13)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Medicin Och Hälsovetenskap
(9)
Pharmacology. Drug Treatments
(8)
Adverse Events
(7)
Environmental Sciences
(7)
Environmental Sciences & Ecology
(7)
Italy
(7)
Public, Environmental & Occupational Health
(7)
Safety
(7)
Side Effects
(7)
Toxicology
(7)
Drug Utilization
(6)
Drugs
(6)
Europe
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems

Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies

The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice

The Approaches to Assess Robustness of Disproportionality Findings in Pharmacovigilance. A Meta-Epidemiological Research

Medication use in Italian nursing homes: preliminary results from the national monitoring system

Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K+ Channel Blockers

Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems

Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction

QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development

Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics

Safety Profile of Sodium-Glucose Co-Transporter-2 Inhibitors: A Global Analysis of Pharmacovigilance Databases

Association between the use of proton pump inhibitors and cardiovascular events: A note of caution

Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes an overview

Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit

QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus

Liver injury with dipeptidyl peptidase-4 (DPP-4) inhibitors (GLIPTINS): signals emerging from the us-fda adverse event reporting system

Hospitalisations by Drug interactions with nsaids in elderly poly-treated patients: outcome research on administrative databases

Oral Presentation: Investigating Hidden Networks in Spontaneous Reporting Systems

Oppenauer's oxidation by paraformaldehyde of piperonyl alcohol to heliotropine

PP016—Exposure to antipsychotics with pro-arrhythmic risk: Combining adverse drug reactions with drug utilization data

Identifying Medications Underlying Communication Atypicalities: A Pharmacosurveillance Study Within the FDA Adverse Event Reporting System

What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System

Hyperacute Multisystem Toxicities with Immune Checkpoint Inhibitors in the FDA Adverse Event Reporting System: The Immune-Adversome

Previous psychiatric disorders and antipsychotic drugs in COVID-19 patients: early findings on possible worse outcome

Aktive Filter

Suchergebnisse filtern